Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,960
  • Shares Outstanding, K 187,271
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -105 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.93
  • Price/Sales 85.82
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings $-0.14 on 11/12/25
  • Next Earnings Date 03/27/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 137.87% (-41.70%)
  • Historical Volatility 79.47%
  • IV Percentile 75%
  • IV Rank 26.23%
  • IV High 318.33% on 07/10/25
  • IV Low 73.71% on 02/20/25
  • Expected Move (DTE 13) 0.1360 (14.49%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 451
  • Volume Avg (30-Day) 1,403
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 75,376
  • Open Int (30-Day) 85,407
  • Expected Range 0.8023 to 1.0743

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8800 +6.63%
on 02/05/26
1.2500 -24.94%
on 01/07/26
-0.1417 (-13.12%)
since 01/06/26
3-Month
0.8800 +6.63%
on 02/05/26
1.4300 -34.38%
on 11/12/25
-0.3717 (-28.37%)
since 11/06/25
52-Week
0.8800 +6.63%
on 02/05/26
4.3800 -78.58%
on 02/07/25
-3.3317 (-78.03%)
since 02/06/25

Most Recent Stories

More News
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

- Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel -  - Expansion of Symvess into other territories, including those in Europe and the Middle...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) -  - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection,...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEVâ„¢) Clinical Results

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels –...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – –...

HUMA : 0.9383 (+5.88%)
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial...

HUMA : 0.9383 (+5.88%)
Humacyte Announces Publication of New Data Comparing Symvessâ„¢ to Autologous Vein in Extremity Arterial Trauma

- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein -...

HUMA : 0.9383 (+5.88%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.0194
2nd Resistance Point 0.9886
1st Resistance Point 0.9635
Last Price 0.9383
1st Support Level 0.9076
2nd Support Level 0.8768
3rd Support Level 0.8517

See More

52-Week High 4.3800
Fibonacci 61.8% 3.0430
Fibonacci 50% 2.6300
Fibonacci 38.2% 2.2170
Last Price 0.9383
52-Week Low 0.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar